Factor Xa, a trypsin-like serine protease that catalyzes the conversion of prothrombin to thrombin, is located at the crucial intersection of the intrinsic and extrinsic pathways. As a result, it plays a crucial role in the final common pathway of the cascade and has emerged as a key target in the research and development of new anticoagulants. A vital protease in the coagulation process called factor Xa is known to have some of its activity controlled by its interactions with sodium ions and factor Va.
Fibrin, the substance that forms the basis of all blood clots, is produced as a result of an intricate series of enzymatic reactions during blood coagulation. The intrinsic and extrinsic pathways, which make up this cascade's two arms, come together at factor Xa to form the common pathway. Prothrombin is activated by factor Xa to become thrombin, which then catalyzes the transformation of fibrinogen into fibrin.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V73138 | Abelacimab (MAA868) | 2098724-83-3 | Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody (mAb) that binds with high affinity to the catalytic domain of FXI and locks it in a zymogen conformation, thereby preventing its activation by FXIIa or thrombin. |
|
V40309 | Apixaban 13CD3 | 1261393-15-0 | Apixaban 13CD3, the deuterated form of Apixaban, is an internal standard (IS) extensively used for the quantification of apixaban which is a coagulation factor Xa inhibitor used to treat and prevent the formation of blood clots. |
|
V73140 | ARC19499 (BAX499) | 1350667-54-7 | ARC19499 is a nucleic acid aptamer that specifically binds to tissue factor pathway inhibitor (TFPI) and blocks the inhibitory effect of TFPI on factor Xa and TF/factor VIIa complexes. |
|
V3917 | BETRIXABAN | 330942-05-7 | Betrixaban (trade name Bevyxxa; formerly PRT054021; MK-4448; PRT-021; MLN-1021 etc. |
|
V3489 | BMS-654457 | 1004551-41-0 | BMS-654457 is a novel, potent, reversible small-molecule inhibitor of factor XIa (FXIa), which binds to human and rabbit FXIa withKis of 0.2 and 0.42 nM, respectively. |
|
V73150 | Boc-Ile-Glu-Gly-Arg-AMC (IEGR-AMC) | 65147-06-0 | Boc-Ile-Glu-Gly-Arg-AMC (IEGR-AMC) is an activating factor X (FXa)-specific fluorescent peptide substrate for the determination of factor VIII. |
|
V73146 | CH3OCO-D-CHA-Gly-Arg-pNA acetate | 80895-10-9 | CH3OCO-D-CHA-Gly-Arg-pNA acetate is the chromogenic substrate of factor Xa. |
|
V79166 | D-Leu-Pro-Arg-Rh110-D-Pro | D-Leu-Pro-Arg-Rh110-D-Pro is a substrate of Factor Xa I (FXIa) with binding affinity. | |
|
V79167 | D-Leu-Pro-Arg-Rh110-D-Pro TFA | D-Leu-Pro-Arg-Rh110-D-Pro TFA is a substrate of Factor Xa I (FXIa) with binding affinity. | |
|
V73135 | Dechloro Rivaroxaban | 1415566-28-7 | Dechloro Rivaroxaban is an orally bioactive, selective inhibitor of Factor Xa. |
|
V73149 | Denecimig (Mim8) | 2488745-86-2 | Denecimig (Mim8) is an activated factor VIII mimetic human bispecific antibody with anti-FIXa and anti-FX arms that effectively stimulates FX activation, resulting in effective hemostasis in vitro and in vivo. |
|
V71918 | Edoxaban impurity 4 (Edoxaban impurity D) | 480452-36-6 | Edoxaban impurity 4 is an impurity in Edoxaban. |
|
V30461 | Edoxaban tosylate (DU-176b) | 480449-71-6 | Edoxaban tosylate (DU176b;DU-176; trade name Savaysa; Lixiana), the tosylate salt of edoxaban, is a marketed anticoagulant drug acting as a potent, selective, orally bioavailable anddirect factor Xa inhibitor. |
|
V73143 | EMD 495235 | 811811-33-3 | EMD 495235 is a potent orally bioactive coagulation factor Xa (factor Xa) inhibitor (antagonist) with IC50 of 5.5 nM and a Ki of 6.8 nM. |
|
V73148 | Frunexian (EP-7041) | 1803270-60-1 | Frunexian (EP-7041) is a selective factor XI/activated factor XI inhibitor targeting Factor XIa. |
|
V73141 | FXa-IN-1 | 441328-10-5 | FXa-IN-1 is an FXa inhibitor (IC50= 3 nM, Ki: 0.7 nM) with considerable oral bioavailability (F) and half-life (in vivo). |
|
V73144 | FXIa-IN-13 | 2629361-99-3 | FXIa-IN-13 (example 1) is a Factor Xa inhibitor (antagonist) with antithrombotic activity. |
|
V73151 | FXIa-IN-6 | 1551459-37-0 | FXIa-IN-6 is a potent inhibitor of FXIa, selective for most related serine proteases (Ki = 0.3 nM). |
|
V73147 | FXIa-IN-7 | 2488952-56-1 | FXIa-IN-7 is an orally bioavailable and selective factor XIa inhibitor (antagonist) with IC50 of 0.4 nM. |
|
V73152 | FXIa-IN-9 | 2816108-87-7 | FXIa-IN-9 (compound 3f) is a potent and specific inhibitor of FXIa. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
